Recent developments include Corcept’s Q3 2026 revenue report of $340.5 million, earnings surpassing prior expectations, and positive Phase 2 clinical trial results for Lifyorli in platinum-resistant ovarian cancer.

• Corcept Therapeutics reported third quarter 2026 product revenue of $340.5 million, reflecting continued growth in its core business [N1].
• The company’s Q3 2026 earnings and revenues surpassed prior expectations, indicating strong operational performance [N2].
• Positive Phase 2 BELLA clinical trial results were announced for Lifyorli in platinum-resistant ovarian cancer, highlighting progress in the company’s pipeline [N3].
• Discussions in recent news consider Lifyorli’s potential to contribute to Corcept’s long-term growth beyond its existing product Korlym [N4].

Corcept’s positive Phase 2 clinical trial results for Lifyorli in platinum-resistant ovarian cancer indicate potential for expanding its product portfolio beyond existing hypercortisolism therapies. The company’s strong revenue growth and net income improvement in recent quarters reflect operational execution and market acceptance. Robust liquidity and capital resources support continued investment in research and development and commercialization efforts.

Risks include the inherent uncertainties of pharmaceutical development, regulatory approvals, and market acceptance of new products such as Lifyorli. Increased operating expenses, particularly in selling, general and administrative areas, may pressure profitability. Market competition and potential changes in healthcare regulations or reimbursement policies could impact revenue streams. Dependence on a limited number of products may expose the company to concentration risk.

Corcept’s moat is supported by its specialized pharmaceutical products targeting niche medical conditions such as hypercortisolism and platinum-resistant ovarian cancer. The company’s established revenue base from existing products and ongoing clinical development of Lifyorli contribute to its competitive positioning. Intellectual property protections, regulatory approvals, and clinical trial progress underpin barriers to entry for competitors in these therapeutic areas.

• Clinical and Regulatory Risk: The success of Lifyorli and other pipeline products depends on clinical trial outcomes and regulatory approvals, which carry inherent uncertainties.
• Market and Competitive Risk: Competition from other pharmaceutical companies and alternative therapies may affect market share and pricing.
• Financial Risk: Fluctuations in operating expenses and reliance on a limited product portfolio could impact financial performance.

• Corcept Therapeutics Inc is a pharmaceutical company with reported product revenue of $340.5 million for Q3 2026.
• The company reported net income of $126.8 million for Q3 2026 and $138.0 million for the nine months ended September 30, 2026.
• Basic earnings per share for Q3 2026 were $1.17 and diluted EPS was $1.01.
• As of September 30, 2026, Corcept had cash and cash equivalents of approximately $98.7 million and short-term investments of about $272.0 million, with total current assets of $533.9 million and current liabilities of $177.7 million, resulting in a current ratio of 3.0 and a cash ratio of 2.09.
• The company’s total assets were $1.034 billion as of September 30, 2026, with stockholders’ equity of $833.7 million.
• Corcept’s operating expenses for Q3 2026 included cost of sales of $4.6 million, research and development expenses of $56.7 million, and selling, general and administrative expenses of $164.4 million.
• The company reported income from operations of $114.7 million for Q3 2026.
• Corcept has a product named Lifyorli, which showed positive Phase 2 BELLA clinical trial results in platinum-resistant ovarian cancer.
• The company’s product portfolio includes hypercortisolism products and Lifyorli as of Q3 2026.
• Recent news highlights Corcept’s Q3 2026 earnings and revenues surpassing prior expectations and a revenue figure of $340.5 million for the quarter.
• The company’s shares outstanding were approximately 109.4 million as of October 22, 2026.
• Corcept has been active in stock repurchase programs and employee stock plans as reflected in its cash flow statements.
• The company’s financial figures and liquidity ratios are derived from the latest SEC 10-Q filing dated November 3, 2026.
• Corcept’s net income and revenue have shown significant growth compared to the prior year periods.
• The company’s research and development expenses decreased compared to the prior year period, while selling, general and administrative expenses increased.
• Corcept’s balance sheet shows strong liquidity with a current ratio of 3.0 and cash ratio above 2 as of September 30, 2026.